Reynolds requests waiver to make certain foods ineligible under SNAP
DES MOINES, Iowa — Governor Kim Reynolds continues to make moves to try to make Iowa's food programs healthier. This time she submitted a request to limit certain foods under SNAP, the food benefit program for low-income families.
The Supplemental Nutrition Assistance Program is a federal program though the USDA.
Reynolds has requested a waiver to make some items ineligible to obtain.
SNAP participants would not be able to buy food products subject to state sales tax. This would include things like candy, breath mints, dried fruit leathers, kettle corn, certain granola bars, soft drinks, certain fruit punches, and more. If it goes through, it would go into effect January 1.
Some local groups do not agree with this, like the Iowa Hunger Coalition.
'I don't think this is really the right way to get low income Iowans eating healthier. We need to be looking at solutions that will increase the affordability and accessibility of fresh fruits and vegetables and other healthy foods for low income Iowans,' said Luke Elzinga, chair of IHC and Policy & Advocacy Manager at DMARC. 'This just really sends the message that the state of Iowa doesn't trust low-income families to make the best food choices for their family. We don't think this ban will be effective, and we'd really like to see some solutions and evidence-based proven interventions like Double Up Food Bucks. The governor actually even mentioned that in her waiver request. So again, we think there are proven solutions to increase healthy eating, but this is not one.'
3 charged in Dallas County fire that caused over $800k in damage to bike trail bridge
In Reynolds' letter to U.S Secretary of Agriculture Brooke Rollins to support her waiver request, Reynolds said, 'We can and must do better for Americans and Iowans by encouraging healthy choices that will help people thrive, not simply providing cash benefits with no focus on holistic well-being.'
Reynolds went on to say that 'Iowa has proven our commitment to innovation and change – all with a focus on improved health and well-being for our families, communities, and farmers.'
Reynolds also just received a USDA waiver to opt out of the federal government's summer feeding program and launch its own program 'Healthy Kids Iowa' to serve low income kids during the summer months. In this program eligible families will have access to $40 of food per month per child, focusing on nutritionally balanced food.
That program has been approved, but the SNAP waiver has not yet.
'I think there's been a lot of work over the years to reduce stigma around food insecurity in general, around participation in SNAP. This is a step in the wrong direction,' Elzinga said. 'This will create more stigma. I think when people are going to a grocery store and maybe purchasing something that is more processed, more calorie dense, but might be cheaper with their SNAP benefits, they are making a rational decision for their household. Here's what I can afford. Here's what I have time to cook. Here's something my kids are going to eat.'
That doesn't mean Elzinga disagrees with the governor about wanting to provide healthy options.
'I think we agree in this goal of wanting to increase healthy eating, let's invest in solutions that get to that affordability piece,' he said.
Iowa News:
NASCAR Cup Series Driver Cole Custer visits elementary students in Newton
Another windy day ahead as temps cool
Reynolds requests waiver to make certain foods ineligible under SNAP
Funko Pop! figures of Caitlin Clark, other WNBA stars coming — how to get them
3 charged in Dallas County fire that caused over $800k in damage to bike trail bridge
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance
WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate." The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation." An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'
Associated Press
an hour ago
- Associated Press
Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance
WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate.' The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation.' An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'
Boston Globe
an hour ago
- Boston Globe
RFK Jr. wants to allow more experimental therapies, acknowledging health risks and threat of ‘charlatans'
'And of course you're going to get a lot of charlatans, and you're going to get people who have bad results,' he added. 'And ultimately, you can't prevent that either way. Leaving the whole thing in the hands of pharma is not working for us.' Advertisement Kennedy cited his own experience at a clinic in Antigua, where he said he received a stem cell treatment that 'enormously' eased his neurological condition, spasmodic dysphonia, which affects his voice and has few treatment options. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up If Kennedy does permit broader use of unauthorized or experimental therapies, he would be reversing long-standing efforts by the FDA to monitor and sometimes police the emerging field. Experts, including some who support alternative medicine, worry that without safeguards, an expansion of such treatments could undermine legitimate development of new therapies. The FDA now narrowly permits stem cell therapies to treat blood and immune disorders. Nearly a decade ago, the field was so loosely regulated that the agency pursued court actions to shut down rogue clinics using unauthorized treatments for a wide array of ailments. Some providers in the United States and in other countries continue to offer experimental stem cell therapies for everything from autism to Alzheimer's to erectile dysfunction. Advertisement The latest move reflects an expansion of Kennedy's drive to dismantle federal health policy to reflect his long-held views, which had so far focused mainly on vaccines, chronic diseases, food dyes and fluoride. A push to open up the field of unregulated stem cell infusions meshes with his oft-stated contention that the FDA is a 'sock puppet' for major drug companies and faces a crisis of distrust. Wellness industry products, he has claimed, are unfairly sidelined. A spokesperson for the Department of Health and Human Services did not respond to requests for comment. Kennedy's statements alarmed experts on the field of sometimes dangerous stem cell infusions -- who noted that many of Kennedy's allies endorse wellness products ranging from red-light therapy to magnetism. 'It's a complete abdication of protection of the public, letting these grifters go forward,' said Timothy Caulfield, a research chair in health law and policy at the University of Alberta in Canada. 'For him to say, 'There are problems with Big Pharma, so we want our opportunity to be bad actors too,' it doesn't make any sense.' One leading expert group, the International Society for Stem Cell Research, reviewed Kennedy's podcast statements and condemned the approach as potentially allowing products that are 'sometimes contaminated with pathogens and are often marketed with scientifically implausible claims.' 'It is critical that the FDA maintain its regulatory authority to protect Americans from these potentially harmful and deceptive products,' the society said in a statement. Advertisement On Thursday, a panelist appearing at an FDA meeting on cell and gene therapies raised a concern about 'snake oil' treatments. Dr. Vinay Prasad, the agency's director of the center for biologics evaluation research, responded, 'We have to regulate the bad actors. We can't let that taint what we do here at the FDA.' Kennedy, who also attended the event, voiced full support for the researchers and biotech executives working on gene therapies for rare diseases, including those who made history by creating a custom gene therapy for an infant named KJ. 'We're going to do everything in our power to sweep away the barriers from you getting those solutions to market and getting them funded, and do everything that we can to support you all,' Kennedy said. On Brecka's podcast in May, Kennedy cited other products that he'd like to see more of, including chelation treatment, which was discussed in a 2015 book edited by him that focused on widely debunked theories about mercury in vaccines and autism and cites 'evidence of chelation's benefits' from a few small studies. One 5-year-old Pennsylvania boy died in 2005 from cardiac arrest after a doctor tried to treat his autism with chelation. Neither Kennedy nor the FDA has released a formal plan to change agency standards for stem cell treatments, which have typically been reviewed by the agency as individual therapies to treat a specific disease. Widening overall access could also happen informally if the agency decided to relax enforcement, an approach the FDA used in the past to indicate that it wouldn't crack down on unauthorized products. During the pandemic, for example, the agency allowed providers to retrofit infusion pumps and ventilators to treat hordes of sick patients. Advertisement During the first Trump administration, the agency's commissioner, Dr. Scott Gottlieb, escalated enforcement against stem cell providers whom he described in 2017 as 'unscrupulous actors who have seized on the clinical promise of regenerative medicine.' The FDA followed through with lawsuits seeking to stop some stem cell providers, including one case that the government won on appeal in the fall. In that case, the agency alleged that one provider, the California Stem Cell Treatment Center, was offering a drug without FDA approval by taking stem cells from a person's fat, manipulating them and infusing them as a remedy for Alzheimer's disease, cancer and arthritis. The agency classifies stem cell treatments as a 'biologic' and approves them much like a drug after careful studies of safety and effectiveness. But the FDA does make exceptions: It does not regulate some treatments if providers say they are extracting and then reinserting a person's cells with minimal manipulation. In March, Kennedy convened a meeting with leaders in the stem cell field. Two people who attended said the gathering was a fact-finding effort to explore a safe way to increase access. To Dr. Noah Raizman, who attended the meeting on behalf of the American Academy of Orthopaedic Surgeons, Kennedy's new pronouncement 'sounds a little more casual and a little bit more emboldened.' In the podcast, Kennedy said that consumers should be able to navigate the industry's claims. 'We don't want to have the Wild West,' Kennedy said. 'We want to make sure that information is out there. But we also want to respect the intelligence of the American people -- the capacity of people who explore the outcomes that are going to benefit them the most.' Advertisement In recent years, stem cell treatments have caused harm in the United States and abroad. Experts at the Pew Research Center tallied more than 350 cases of side effects including life-threatening blood infections, heart attacks and tumors. One Boston neurosurgeon discovered a huge mass of bloody tissue in the lower spine of a man who had received unproven stem cell treatments in Mexico, China and Argentina. Three patients were blinded after stem cell treatments at a Florida clinic. The FDA prevailed in getting a court order to stop the clinic from operating. The field of stem cell treatments is so complex that the Harvard Medical School created a free course to help doctors navigate patient questions, said Insoo Hyun, the director of life sciences at the Museum of Science in Boston. More than 110 stem cell clinical studies are advancing under regulatory oversight. In one, scientists at the National Institutes of Health are using retinal cells developed from patients' blood to try to treat vision loss in older adults -- and follow them for 15 years. In another study aimed at helping patients with Parkinson's disease, researchers at a biotech company in California are exploring the safety of infusing dopamine-producing neurons in a region of the brain that controls the body's movements. A Chinese company is studying a treatment for heart failure that involves transplanting cardiac muscle cells into the heart. Some providers sidestep the costly, yearslong process of careful work that can lead to an FDA approval. Among them is Dr. Chadwick Prodromos, a Chicago doctor who offers stem cell treatments in Antigua. Kennedy welcomed him warmly at the March meeting, Raizman recalled. Reached for comment, Prodromos' office said that he was in Antigua doing treatments and was not available. Advertisement In an April interview on YouTube, Prodromos said that he was still in touch with the FDA about stem cell treatments that could help people 'without allowing scams and things that aren't valid. And you know, it's a tricky proposition.' A website for Prodromos' clinic says that he and colleagues offer injections in Antigua into the joints, back, neck, scalp, penis and pelvic floor for an array of conditions including autism, thinning hair and lupus. He uses AlloRX cells, which are derived from the umbilical cord, in a manner that in the United States would require an FDA-cleared clinical trial. People can seek out unregulated treatments using their own cells that are processed, purified and amplified in different ways. They can also find treatments using others' cells that vary widely in quality and sterility. Some low-quality clinics process cells in a back room, which is the opposite of a clinical-grade cell processing site. Hyun said he recently toured one in the Netherlands that used specialized air filtering, layers of gowns and a ban on bacteria-laden cellphones in their sterile area. 'It's kind of like you're entering a space station,' he said. Ultimately, Caulfield said, many unauthorized stem cell providers adopt the language of biotech and regenerative medicine, post glowing patient testimonials and exploit patients who are desperate for a cure. This article originally appeared in .
